The first report of institutional cancer registry in a center located in Medellín, Colombia

Purpose: This is the first report of an institutional-based cancer registry in Clínica de Oncología Astorga, in Medellín, Colombia. It was created to produce local information on socio-demographic and clinical characteristics, therapies, and survival outcomes of patients with the most frequent tumor...

Full description

Saved in:
Bibliographic Details
Published inRevista Colombiana de Hematología y Oncología Vol. 10; no. 1
Main Authors Preciado Franco, Beatriz Elena, Moran Ortiz, Diego, Lema, Camila, Fernandez Turizo, Maria Jose, Calle Correa, Esteban, Pineda Álvarez, Mateo, Ospina Sánchez, Juan Pablo, Villegas Sierra, Laura Elisa, Luján Piedrahita, Mauricio, Egurrola-Pedraza, Jorge A., Lema, Mauricio
Format Journal Article
LanguageEnglish
Published 03.08.2023
Online AccessGet full text

Cover

Loading…
More Information
Summary:Purpose: This is the first report of an institutional-based cancer registry in Clínica de Oncología Astorga, in Medellín, Colombia. It was created to produce local information on socio-demographic and clinical characteristics, therapies, and survival outcomes of patients with the most frequent tumors in the institution.  Methods: All consecutive patients with cancers of the breast (BC), prostate (PC), lung (LC), colorectal (CRC), ovarian, stomach, pancreas, cervical, and melanoma, diagnosed after January 1/2019, and treated at the institution were included. A description of the entire cohort and of the five most frequent tumor types was performed. Kaplan-Meier curves for each tumor stage were used to estimate overall survival (OS) and progression-free survival (PFS). Statistical analysis was performed using SPSS v22. Results: Data from 729 patients were analyzed. The median follow-up was 12.0 months (IQR 5.8-18.1). The main diagnoses were BC, PC, CRC, LC, and cervical cancer in 57.2%, 10.2%, 8.0%, 7.7%, and 5.8% of patients, respectively. The most frequent stage at diagnosis was: stage II for BC (36.6%) and PC (35.1%), stage III for CRC (62.1%) and cervical cancer (50.0%), and stage IV for LC (62.5%).  In BC cases, the median PFS for stage IV patients was 10.8 months (95%CI: 8.7-13.0). In LC cases, median PFS and OS for stage IV were 5.6 months (95%CI: 4.1-7.0), and 6.8 months (95%CI: 2.5-11.1), respectively.  Conclusion: Even though follow-up is short in this first report, PFS for metastatic BC and PFS and OS for metastatic LC reflect the aggressive nature of these conditions in Colombia.
ISSN:2256-2877
2256-2915
DOI:10.51643/22562915.517